Summary
The effects of penbutolol (Hoe 893 d), a new non-selective beta-receptor blocking agent, were studied in 5 patients with moderate hypertension. Initially, it was shown that 2–4 mg given orally once or twice daily tended to lower blood pressure and pulse rate, both at rest and following submaximal work. In prolonged trials (3–8 months) 40–60 mg/day were required to produce an acceptable antihypertensive effect. Penbutolol had no effect on the normal increase in plasma noradrenaline and adrenaline on standing, nor did it alter basal urinary catecholamine excretion. Submaximal work caused no significant change in plasma catecholamines before treatment, but there was a marked rise both in plasma noradrenaline and adrenaline during treatment with penbutolol. In short term studies there was a fall in plasma renin by 4 hours after oral administration of penbutolol 2–4 mg, which persisted for 24 hours. Prolonged treatment with penbutolol 20–30 mg twice daily inhibited renin production under basal conditions and following submaximal work, as well as lowered basal urinary aldosterone excretion. In one patient slight asthmatic symptoms appeared after treatment for 3 months with penbutolol. In other respects penbutolol was well tolerated.
Similar content being viewed by others
References
Kuramoto, K., Murata, K., Yazaki, Y., Ikeda, M., Nakao, K.: Hemodynamics in the juvenile hypertension with special reference to the response to propranolol. Jap. Circulat. J. (En.)32 981–987 (1968)
Shinebourne, E., Fleming, J., Hamer, J.: Effects of beta-adrenergic blockade during exercise in hypertensive and ischaemic heart-disease. Lancet1967 II 1217–1220
Frohlich, E.D., Tarazi, R.C., Dustan, H.P., Page, I.H.: The paradox of beta-adrenergic blockade in hypertension. Circulation37 417–423 (1968)
Wilson, D.F., Watson, O.F., Peel, J.S., Langley, R.B., Turner, A.S.: Some hemodynamic effects of Trasicor (Ciba 39,089/Ba). N.Z. med. J.68 145–149 (1968)
Prichard, B.N.C., Shinebourne, E., Fleming, J., Hamer, J.: Hemodynamic studies in hypertensive patients treated by oral propranolol. Brit. Heart J.32 236–240 (1970)
Tarazi, R.C., Dustan, H.P.: Beta-adrenergic blockade in hypertension. Amer. J. Cardiol.29 633–640 (1972)
Hansson, L.: Beta-adrenergic blockade in essential hypertension. Effects of propranolol on hemodynamic parameters and plasma renin activity. Acta med. scand. suppl.550 20–25 (1973)
Lund-Johansen, P.: Hemodynamic changes at rest and during exercise in long-term beta-blocker therapy of essential hypertension. Acta med. scand.195 117–121 (1974)
Winer, N., Chokshi, D.S., Yoon, M.S., Freedman, A.D.: Adrenergic receptor mediation of renin secretion. J. clin. Endocr.29 1168–1175 (1969)
Michelakis, A.M., McAllister, R.G.: The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J. clin. Endocr.34 386–394 (1972)
Bravo, E.L., Tarazi, R.C., Dustan, H.P.: On the mechanism of suppressed plasma renin activity during beta-adrenergic blockade with propranolol. J. Lab. clin. Med.83 119–128 (1974)
Bühler, F.R., Laragh, J.H., Baer, L.B., Vaughan, E.D. Jr., Brunner, H.R.: Propranolol inhibition of renin secretion. New Engl. J. Med.287 1209–1214 (1972)
Hamet, P., Kuchel, O., Cuche, J.L., Boucher, R., Genest, J.: Effect of propranolol on cyclic AMP excretion and plasma renin activity in labile essential hypertension. Canad. med. Ass. J.109 1099–1103 (1973)
Esler, M.D., Nestel, P.J.: Evaluation of practolol in hypertension. Effects on sympathetic nervous system and renin responsiveness. Brit. Heart J.35 469–474 (1973)
Härtfelder, G., Lessenich, H., Schmitt, K.: Penbutolol (Hoe 893 d), ein neues stark wirksames Beta-Sympatholytikum mit langer Wirkungsdauer. Arzneimittel.-Forsch.22 930–932 (1972)
Engelman, K., Portnoy, B.: A sensitive double-isotope derivative assay for norepinephrine and epinephrine. Circulat. Res.26 53–57 (1970)
Euler, U.S. von, Lishajko, F.: Improved technique for the fluorimetric estimation of catecholamines. Acta physiol. scand.51 348–356 (1961)
Haber, E., Koerner, T., Page, L.B., Kliman, B., Purnode, A.: Application of a radio-immunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J. clin. Endocr.29 1349–1355 (1969)
Kliman, B., Peterson, R.E.: Double isotope derivative assay of aldosterone in biological extracts. J. biol. Chem.235 1639–1648 (1960)
Christensen, N.J., Brandsborg, O.: The relationship between plasma catecholamine concentration and pulse rate during exercise and standing. Europ. J. clin. Invest.3 299–306 (1973)
Hertting, G., LaBrosse, E.H.: Biliary and urinary excretion of metabolites of 7-H3-epinephrine in the rat. J. biol. Chem.237 2291–2295 (1962)
Häggendal, J.: Some further aspects on the release of the adrenergic transmitter. In: New aspects of storage and release mechanisms of catecholamines. Bayer Symposim II. (eds: H.J. Schümann, G. Kroneberg) pp. 100–109. Berlin, Heidelberg, New York: Springer-Verlag 1970
Hedqvist, P.: Role of the alpha-receptor in the control of noradrenaline release from sympathetic nerves. Acta physiol. scand.90 158–165 (1974)
Stjärne, L.: Stereoselectivity of presynaptic alpha-adrenoceptors involved in feedback control of sympathetic neurotransmitter secretion. Acta physiol. scand.90 286–288 (1974)
Tarazi, R.C., Frohlich, E.D., Dustan, H.P.: Plasma volume changes with long-term beta-adrenergic blockade. Amer. Heart J.82 770–776 (1971)
Julius, S., Pascual, A.V., Abbrecht, P.H., London, R.: Effect of beta-adrenergic blockade on plasma volume in human subjects. Proc. Soc. exp. Biol. (N.Y.)140 982–985 (1972)
Sealey, J.E., Clark, I., Bull, M.B., Laragh, J.H.: Potassium balance and the control of renin secretion. J. clin. Invest.49 2119–2127 (1970)
Brunner, H.R., Baer, L., Sealey, J.E., Ledingham, J.G.G., Laragh, J.H.: The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. J. clin. Invest.49 2128–2138 (1970)
Hökfelt, B., Hedeland, H., Hansson, B.-G.: The effect of clonidine and penbutolol, respectively on catecholamines in blood and urine, plasma renin activity and urinary aldosterone in hypertensive patients. Arch. Int. Pharmacodyn. Ther.213 307–321 (1975)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hansson, B.G., Hökfelt, B. Long term treatment of moderate hypertension with penbutolol (Hoe 893d). I. Effects on blood pressure, pulse rate, catecholamines in blood and urine, plasma renin activity and urinary aldosterone under basal conditions and following exercise. Eur J Clin Pharmacol 9, 9–19 (1975). https://doi.org/10.1007/BF00613424
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00613424